Monday, January 3, 2022

Twitter bans mRNA pioneer Dr. Robert Malone after he raised alarm about Pfizer COVID shot dangers

Prominent U.S. virologist Dr. Robert Malone's Twitter account was suspended last week after he shared a video pointing out the serious risks posed by COVID-19 injections.

"Over the past year, I have had a few notices from Twitter that there was a complaint about a post but that no action was taken," Malone told the Epoch Times Friday, adding he "Received no warning prior to the banning."

Malone, who has faced repeated attacks for expressing views that run contrary to the mainstream narrative on COVID-19 and the injections marketed to treat it, told The Epoch Times that last week's suspension from Twitter was in response to content he shared regarding the medical risks of COVID-19 drugs which Twitter stated was "Misleading and potentially harmful."

Well-known for contributing to the invention of mRNA technology used in the Pfizer and Moderna jabs, Malone was scientifically trained at the University of California at Davis, the University of California at San Diego, and at the Salk Institute Molecular Biology and Virology laboratories.

While it's unclear whether a specific tweet triggered the suspension, just prior to his ban Malone had shared a video published by Canadian Covid Care Alliance entitled "The Pfizer Inoculations For COVID-19 - More Harm Than Good.".

Malone provided the Epoch Times with a screenshot from Twitter containing a message stating that his suspension was due to an alleged violation of the platform's "Policy on spreading misleading and potentially harmful information related to COVID-19.".

Malone's suspension from Twitter came days before the doctor was slated to participate in an interview with megastar podcaster Joe Rogan, and spurred both Rogan and Malone to join up-and-coming social media platform GETTR, which advertises itself as a free-speech alternative to Twitter.

https://www.lifesitenews.com/news/twitter-bans-mrna-pioneer-after-he-warned-about-covid-shots/?utm_source=featured&utm_campaign=usa 

No comments: